SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #1
Under the Securities Exchange Act of 1934
GENSIA SICOR, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.01 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
372450 10 6
-----------------
(CUSIP Number)
Rebecca R. Tilden,Esq.
Vice President and Assistant Secretary, HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
(816) 966-4000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 24, 1997
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box. [ ]
Page 1 of 4
There are no Exhibits
<PAGE> 2
CUSIP No. 372450 10 6
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 3,397,061*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 3,397,061*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 3,397,061*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 4.6%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
*The filing of this Statement shall not be construed as an admission that
the reporting person is, for the purposes of Section 13(d) of the
Securities Exchange Act of 1934, the beneficial owner of any securities
covered by this Statement.
<PAGE> 3
This Amendment to the Statement on Schedule 13D (the "Schedule 13D")
with respect to the Common Stock of Gensia Sicor, Inc. (the "Issuer"), of
HMR Pharma, Inc., a Delaware corporation ("Pharma"), is filed solely to
report the termination of the Schedule 13D filing obligation of Pharma with
respect to beneficial ownership of securities of the Issuer.
Item 5 of this Statement on Schedule 13D is hereby amended to read in
its entirety as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
- ------- ------------------------------------
As a result of increases in the number of shares outstanding of the
Issuer, Pharma is no longer subject to the reporting requirements of
Section 13(d) of the Securities Exchange Act of 1934, as amended.
<PAGE> 4
SIGNATURES
----------
After reasonable inquiry and to the best of their knowledge and
belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
HMR PHARMA, INC.
Date: October 27, 1997 By: /s/ Rebecca R. Tilden
Rebecca R. Tilden
Vice President and
Assistant Secretary
